Golimumab should be used in patients with psoriatic polyarticular idiopathic juvenile arthritis and psoriatic arthritis, with treatment responses expected to mirror the efficacy demonstrated by older TNF-a inhibitor therapies. This evidence concerns the gene TNF and psoriatic arthritis.